We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 05. | 장 마감 후 (AMC) | — | — | — | $9.65M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-0.47 | — | — | $6.72M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-1.19 | — | — | $18.14M |
Consensus PT $19.17 · 5 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 01. 26. | HC Wainwright & Co. | — | 의견 유지 | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 03. 14. | Ladenburg Thalmann | — | 의견 유지 | Buy → Buy | — | Ladenburg Thalmann: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-0.9 | — | — | $11.58M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 19,121 | $115.3M | 0.00% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 19,421 | $87.1M | 0.00% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Stored first · Google News · Yahoo Finance (English)
Electrocore CFO and interim president Lev sells $60,003 of company stock By Investing.com - Investing.com South Africa
Electrocore CFO and interim president Lev sells $60,003 of company stock By Investing.com Investing.com South Africa
electroCore (ECOR) CFO sells 6,667 shares in open-market trade - Stock Titan
electroCore (ECOR) CFO sells 6,667 shares in open-market trade Stock Titan
electroCore, Inc. Hits New 52-Week High of $9.18, Surpassing Previous Milestones - Markets Mojo
electroCore, Inc. Hits New 52-Week High of $9.18, Surpassing Previous Milestones Markets Mojo
electroCore, Inc. Hits New 52-Week High of $9.64, Reflecting Strong Growth - Markets Mojo
electroCore, Inc. Hits New 52-Week High of $9.64, Reflecting Strong Growth Markets Mojo
electroCore (ECOR) insider sale: 3,000 shares for $19,500 reported - Stock Titan
electroCore (ECOR) insider sale: 3,000 shares for $19,500 reported Stock Titan
ECOR (NASDAQ: ECOR) files Form 144 notice reporting proposed insider sales - Stock Titan
ECOR (NASDAQ: ECOR) files Form 144 notice reporting proposed insider sales Stock Titan